PMID- 12525568
OWN - NLM
STAT- MEDLINE
DCOM- 20030321
LR  - 20190605
IS  - 0741-5400 (Print)
IS  - 0741-5400 (Linking)
VI  - 73
IP  - 1
DP  - 2003 Jan
TI  - Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and 
      IgE-mediated histamine release in human basophils and downmodulate expression of 
      the basophil-activation antigen CD203c/E-NPP3.
PG  - 107-17
AB  - Recent data suggest that the statins, apart from their lipid-lowering activity, 
      exhibit profound anti-inflammatory effects. Basophils are major proinflammatory 
      effector cells in diverse pathologic reactions. We have examined the in vitro 
      effects of five different statins on primary human basophils, their progenitors, 
      and the basophil cell line KU-812. Preincubation of blood basophils with 
      cerivastatin or atorvastatin (0.1-100 microM) for 24 h reduced their capacity to 
      release histamine on immunoglobulin E (IgE)-dependent stimulation in a 
      dose-dependent manner. These statins also inhibited IgE-dependent up-regulation 
      of the basophil-activation antigen CD203c. Moreover, both statins suppressed 
      interleukin-3-induced differentiation of basophils from their progenitors as well 
      as (3)H-thymidine uptake in KU-812 cells. All inhibitory effects of cerivastatin 
      and atorvastatin were reversed by mevalonic acid (200 microM). The other statins 
      tested (lovastatin, simvastatin, pravastatin) did not show significant inhibitory 
      effects on basophils. Together, these data identify cerivastatin and atorvastatin 
      as novel inhibitors of growth and activation of human basophils.
FAU - Majlesi, Yasamin
AU  - Majlesi Y
AD  - Department of Internal Medicine I, Division of Hematology & Hemostaseology, 
      University of Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
FAU - Samorapoompichit, Puchit
AU  - Samorapoompichit P
FAU - Hauswirth, Alexander W
AU  - Hauswirth AW
FAU - Schernthaner, Gerit-Holger
AU  - Schernthaner GH
FAU - Ghannadan, Minoo
AU  - Ghannadan M
FAU - Baghestanian, Mehrdad
AU  - Baghestanian M
FAU - Rezaie-Majd, Abdolreza
AU  - Rezaie-Majd A
FAU - Valenta, Rudolf
AU  - Valenta R
FAU - Sperr, Wolfgang R
AU  - Sperr WR
FAU - Buhring, Hans-Jorg
AU  - Buhring HJ
FAU - Valent, Peter
AU  - Valent P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Leukoc Biol
JT  - Journal of leukocyte biology
JID - 8405628
RN  - 0 (Antigens, CD)
RN  - 0 (ENPP3 protein, human)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Interleukin-3)
RN  - 0 (Pyridines)
RN  - 0 (Pyrroles)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - A0JWA85V8F (Atorvastatin)
RN  - AM91H2KS67 (cerivastatin)
RN  - EC 3.1.4.- (Phosphoric Diester Hydrolases)
RN  - EC 3.6.1.- (Pyrophosphatases)
SB  - IM
MH  - Antigens, CD/analysis
MH  - Atorvastatin
MH  - Basophils/cytology/*drug effects
MH  - Cell Differentiation/drug effects
MH  - Cell Division/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Down-Regulation/drug effects
MH  - Heptanoic Acids/*pharmacology
MH  - Histamine Release/*drug effects
MH  - Humans
MH  - Immunoglobulin E/immunology
MH  - Interleukin-3/physiology
MH  - Phosphoric Diester Hydrolases/biosynthesis/*drug effects
MH  - Pyridines/*pharmacology
MH  - Pyrophosphatases/biosynthesis/*drug effects
MH  - Pyrroles/*pharmacology
EDAT- 2003/01/15 04:00
MHDA- 2003/03/22 04:00
CRDT- 2003/01/15 04:00
PHST- 2003/01/15 04:00 [pubmed]
PHST- 2003/03/22 04:00 [medline]
PHST- 2003/01/15 04:00 [entrez]
AID - 10.1189/jlb.0202075 [doi]
PST - ppublish
SO  - J Leukoc Biol. 2003 Jan;73(1):107-17. doi: 10.1189/jlb.0202075.